Drug duo tested to shrink tumors before kidney cancer surgery
NCT ID NCT06114940
Summary
This study tested whether giving two drugs—an immunotherapy (toripalimab) and a targeted therapy (lenvatinib)—before and sometimes after kidney removal surgery could help shrink tumors and improve outcomes for people with kidney cancer. It aimed to see how much the treatment reduced the amount of cancer cells left in the tumor area after surgery. The trial was stopped early and only enrolled 17 of a planned 69 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Nanjing, Jiangsu, 210000, China
Conditions
Explore the condition pages connected to this study.